Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Brief: Essex Bio-Technology Received Positive Outcome Of U.S. FDA - Second Phase 3 Clinical Trial In Dry Eye Disease

Feb 24 (Reuters) - Essex Bio-Technology Ltd  1061.HK :
    * POSITIVE OUTCOME OF U.S. FDA- SECOND PHASE 3 CLINICAL
TRIAL- IN
DRY EYE DISEASE

Source text for Eikon:  ID:nHKS2pwfD9 
Further company coverage:  1061.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Essex Bio-Technology

See all news